Singapore: The Asian Regenerative Center for Cellular Therapies (ARCCT), which is expected to open in September 2012, will provide cellular regeneration therapies to treat conditions related to aging and chronic pain.

The ARCCT will be a pioneer and a leader in medical research and innovations, immune and stem cell research and therapies, and in wellness and anti-aging programs. The research and therapies of the ARCCT will serve to advance knowledge of cellular regeneration medicine in Asia and the rest of the world.

Some of the medical services and applications that the ARCCT will offer include immune and stem cell storage; genetic tests; muscular dysfunction diseases (orthopedic and reconstructive); chronic pain; antiaging therapies; organic vaccines; as well as cosmetic and dermatologic treatments. "It is the ARCCT's vision to bring most advanced technology equipment available today for stem cell therapy or regenerative cellular therapy.

Dr Cynthia Carrion, president, Asian Holistic Medical Alliance (AHMA), said that, "This technology and machinery has never been brought to the Philippines prior to the ARCCT's establishment." The AHMA owns and administers the ARCCT in a joint venture with the US-based Keller Medical Institute.

According to Dr Carrion, the ARCCT is envisioned to make the Philippines a hub for regenerative cellular therapies in Asia. It will not only offer medical treatments but also, just as importantly, the latest and best research on the present and future applications of stem cell technology.

Another interesting application of cellular regeneration technology is in the storage of our immune cells. By the time a human being reaches the fifth decade of life, his or her immune cells have grown old. This compromises a person's immune system, reducing the body's capacity to fight diseases and the effects of old age. Cellular regeneration technology allows us to harvest immune cells, and to multiply and store them as healthy immune cells.

The ARCCT facility is composed of world renowned physicians in cellular regeneration medicine, including a Nobel Prize winner, under the leadership of its CEO and medical director, Dr Robert Keller.